Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $189.1 million.

  • Intellia Therapeutics' Total Non-Current Liabilities was N/A to $189.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $189.1 million, marking a year-over-year change of. This contributed to the annual value of $189.1 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Intellia Therapeutics reported Total Non-Current Liabilities of $189.1 million as of FY2024, which was down 27.43% from $260.5 million recorded in FY2022.
  • Intellia Therapeutics' Total Non-Current Liabilities' 5-year high stood at $260.5 million during FY2022, with a 5-year trough of $189.1 million in FY2024.
  • In the last 2 years, Intellia Therapeutics' Total Non-Current Liabilities had a median value of $224.8 million in 2022 and averaged $224.8 million.